Chemomab Therapeutics (CMMB) Restructuring Costs (2020)

Chemomab Therapeutics' (CMMB) quarterly Restructuring Costs came in at -$699000.0 in Q4 2020, down 984.81% on a QoQ basis from $79000.0 in Q3 2020.

Chemomab Therapeutics (CMMB) Restructuring Costs (2020) Analysis & Trends

Chemomab Therapeutics (CMMB) has 1 years of Restructuring Costs data on file, last reported at -$699000.0 in Q4 2020.

Quarterly Restructuring Costs changed N/A year-over-year to -$699000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $50000.0 (changed N/A YoY) and the FY2021 annual result came in at $216000.0, up 332.0% from the prior year.
Restructuring Costs eased to -$699000.0 in Q4 2020, from $79000.0 in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $670000.0 in Q1 2020 to a low of -$699000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Chemomab Therapeutics	13.33 Mn	2.96 Mn	-

Download Data